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Abstract
Background: Neuropathic pain in the trigeminal system is frequently observed in clinic, but the mechanisms
involved are largely unknown. In addition, the function of immune cells and related chemicals in the mechanism of
pain has been recognized, whereas few studies have addressed the potential role of chemokines in the trigeminal
system in chronic pain. The present study was undertaken to test the hypothesis that chemokine C-C motif ligand 2
(CCL2)-chemokine C-C motif receptor 2 (CCR2) signaling in the trigeminal nucleus is involved in the maintenance of
trigeminal neuropathic pain.
Methods: The inferior alveolar nerve and mental nerve transection (IAMNT) was used to induce trigeminal
neuropathic pain. The expression of ATF3, CCL2, glial fibrillary acidic protein (GFAP), and CCR2 were detected by
immunofluorescence histochemical staining and western blot. The cellular localization of CCL2 and CCR2 were
examined by immunofluorescence double staining. The effect of a selective CCR2 antagonist, RS504393 on pain
hypersensitivity was checked by behavioral testing.
Results: IAMNT induced persistent (>21 days) heat hyperalgesia of the orofacial region and ATF3 expression in the
mandibular division of the trigeminal ganglion. Meanwhile, CCL2 expression was increased in the medullary dorsal
horn (MDH) from 3 days to 21 days after IAMNT. The induced CCL2 was colocalized with astroglial marker GFAP, but
not with neuronal marker NeuN or microglial marker OX-42. Astrocytes activation was also found in the MDH and it
started at 3 days, peaked at 10 days and maintained at 21 days after IAMNT. In addition, CCR2 was upregulated by
IAMNT in the ipsilateral medulla and lasted for more than 21 days. CCR2 was mainly colocalized with NeuN and few
cells were colocalized with GFAP. Finally, intracisternal injection of CCR2 antagonist, RS504393 (1, 10 μg) significantly
attenuated IAMNT-induced heat hyperalgesia.
Conclusion: The data suggest that CCL2-CCR2 signaling may be involved in the maintenance of orofacial
neuropathic pain via astroglial–neuronal interaction. Targeting CCL2-CCR2 signaling may be a potentially important
new treatment strategy for trigeminal neuralgia.
Background
Neuropathic pain resulting from many types of injury to
the nervous system is a devastating disease. The
mechanisms by which nerve injury develops neuropathic
pain have remained largely unknown. It was generally
believed that only neurons and their neural circuits were
responsible for the development and maintenance of
neuropathic pain. In recent years, it is increasingly
recognized that non-neuronal cells such as immune cells
and glial cells also play a critical role in the pathogenesis
of neuropathic pain [1-5]. Both astrocytes and microglia
were activated in the spinal cord [6-8] and trigeminal nu-
cleus [9-11] following peripheral nerve injuries such as
nerve transection and ligation. The activated glial cells
can contribute to the enhancement and maintenance of
neuropathic pain by releasing potent neuromodulators,
such as growth factors, proinflammatory cytokines and
chemokines [12-16]. In particular, chemokines have been
demonstrated to be involved in neuroinflammation at
different anatomical locations, including injured nerve,
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dorsal root ganglion (DRG), spinal cord, and brain [17-20]
and contribute to chronic pain processing [16].
Chemokine C-C motif ligand 2 (CCL2), also known as
monocyte chemoattractant protein 1 (MCP-1), is a mem-
ber of the chemokines family and can specifically recruit
monocytes to sites of inflammation, infection, trauma,
toxin exposure, and ischemia. The biological effects of
CCL2 are mediated via interaction with its G protein-
coupled receptor, chemokines C-C motif receptor 2
(CCR2) [21]. Targets of CCR2 signaling include mitogen-
activated protein kinase (MAPK) [22], an important
intracellular signaling in regulating neural plasticity and
inflammatory responses [23], indicating CCL2-CCR2
may be involved in neuroinflammation and chronic pain.
Indeed, behavioral studies have shown that mice lacking
CCR2 display a substantial reduction in mechanical
allodynia after partial ligation of the sciatic nerve
[24,25]. Mice overexpressing CCL2 in astrocytes exhibit
enhanced pain sensitivity [26]. Although CCL2 and
CCR2 expression are well documented in the DRG in
conditions of nerve injury [27-30] and tissue inflamma-
tion [31], the expression of CCL2 and CCR2 in the
spinal cord is debated [32,33]. In addition, whether
CCL2-CCR2 signaling is involved in trigeminal neuro-
pathic pain remains unknown.
The trigeminal spinal subnucleus caudalis, which has a
laminated structure similar to the spinal dorsal horn and
is often referred as the medullary dorsal horn (MDH),
has been generally considered to play an essential role in
trigeminal pain transmission [34,35]. Several animal
models, such as injuries to the lingual nerve, infraorbital
nerve (ION), inferior alveolar nerve (IAN), or the infer-
ior alveolar nerve and mental nerve (IAMN) have been
used to study the trigeminal neuropathic pain [9,10,36-40].
In addition, it was shown that after transection of IAN or
IAMN, the whisker pad area, which is innervated by the
ION, showed hypersensitivity to mechanical stimulation
[9,40], suggesting the secondary hyperalgesia was induced.
In the present study, we transected the IAMN, tested heat
hyperalgesia in the whisker pad area, and investigated the
expression and cellular distribution of CCL2 and CCR2
in the MDH after IAMN transection (IAMNT) in mice.
The analgesic effect of CCR2 antagonist, RS504393 on
IAMNT-induced heat hyperalgesia was also investigated at
day 3 and day 10 after IAMNT.
Methods
Animals and surgery
Adult CD1 mice (male, 25–30 g) were purchased from
the Experimental Animal Center of Nanjing Medical
University. Mice were housed in plastic cages, and
maintained on a 12:12 hour light/dark circle under con-
ditions of 23 ± 1 °C with food and water available. All
surgical and experimental procedures were reviewed
and approved by the Animal Use and Care Committee
for Research and Education of Nantong University. Ani-
mal treatments were performed according to the
Guidelines of the International Association for the
Study of Pain [41]. Before the experiments, the animals
were allowed to habituate to the housing facility for
3 days. The IAN and mental nerve (MN) transection
were made as described by Piao et al. [9]. In brief, mice
were anesthetized with sodium pentobarbital (40–
50 mg/kg). The facial skin over the left masseter muscle
was cut and the mandibular bone was exposed. The
bone surface was carefully removed and both the IAN
and MN were exposed and transected (Figure 1A).
Then the cutaneous tissue was sutured. For sham-
operated mice, the facial skin and the masseter muscle
were similarly incised and the IAN/MN was exposed,
but no nerve transection was carried out.
Drugs and administration
The selective CCR2 antagonist, RS504393 was purchased
from Tocris (Bristol, UK). For intracisternal injection,
animals were anesthetized with isoflurane. The medulla
Figure 1 Image showing the anatomical structure of the MN
and the IAN and heat hyperalgesia produced after IAMNT. (A)
after removing the mandibular bone, the mandibular nerve, MN and
IAN were exposed. Transection was made on the MN and IAN. (B)
IAMNT induced significant decrease of head-withdrawal latency
(HWL) on the ipsilateral facial skin. There were no significant changes
of HWL in naïve and sham-operated mice. * P< 0.05, ** P< 0.01, ***
P< 0.001, compared to sham-operated mice. n = 6 for each group.
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puncture was made with a 30 G needle between the oc-
cipital bone and the atlas to deliver the reagents (10 μl)
to the cerebral spinal fluid.
Behavioral experiments
Animals were habituated to the testing environment
daily for at least two days before baseline testing. The
room temperature and humidity remained stable for all
experiments. Animals were put in plastic boxes and
allowed 30 minutes for habituation before examination.
A heat stimulus was applied to the maxillary whisker
pad skin by radiant heat (IITC Life Science, Woodland
Hills, CA, USA). Heat sensitivity was expressed as head-
withdrawal latency (HWL). The radiant heat intensity
was adjusted so that basal HWL is between 10–13 sec-
onds, with a cut-off of 18 seconds to prevent tissue
damage.
Immunohistochemistry
After appropriate survival times, animals were deeply
anesthetized with isoflurane and perfused through the
ascending aorta with phosphate-buffered saline (PBS)
followed by 4% paraformaldehyde in 0.1 MPB. After the
perfusion, the medulla and upper cervical cord and tri-
geminal ganglion (TG) were removed and postfixed in
the same fixative overnight. The medulla sections
(30 μm, free-floating) and TG sections (14 μm) were cut
in a cryostat and processed for immunofluorescence
staining. The sections were first blocked with 2% goat or
donkey serum for 1 hour at room temperature and then
incubated overnight at 4 °C with the following primary
antibodies: ATF3 antibody (rabbit, 1:1000, Santa Cruz,
Santa Cruz, CA, USA), CCL-2 antibody (rabbit, 1:500,
Millipore, Billerica, MA, USA), glial fibrillary acidic pro-
tein (GFAP) antibody (mouse, 1:5000, Millipore), OX-42
antibody (mouse, 1:5000, Serotec, Kidlington, Orford,
UK), NeuN antibody (mouse, 1:5000, Millipore), Iba-1
antibody (rabbit, 1:5000, Wako, Tokyo, Japan), and
CCR2 antibody (goat, 1:50, Santa Cruz). The sections
were then incubated for 1 hour at room temperature
with Cy3- or FITC-conjugated secondary antibodies
(1:400, Jackson ImmunoResearch, West Grove, PA,
USA). For double immunofluorescence, sections were
incubated with a mixture of mouse and rabbit (or goat)
primary antibodies followed by a mixture of FITC- and
CY3-conjugated secondary antibodies. The stained sec-
tions were examined with a Leica fluorescence micro-
scope, and images were captured with a CCD Spot
camera. The sections with double staining were imaged
with an Olympus FV10i confocal microscope.
FG retrograde labeling
Naïve or IAMNT-operated (1 day) mice were anesthe-
tized with isoflurane and 4 μl of 2% FG dye was
subcutaneously injected into the mental skin. Two days
later, the animals were perfused and the TGs were dis-
sected and cut as described above.
Western blot
After appropriate survival times, animals were transcar-
dially perfused with 0.01 M PBS. The medulla was dis-
sected. The tissues were homogenized in a lysis buffer
containing protease and phosphatase inhibitors (Sigma,
St Louis, MO, USA). Protein concentrations were deter-
mined by BCA Protein Assay (Pierce, Rockford, IL,
USA). Thirty μg of proteins were loaded for each lane
and separated on SDS-PAGE gel. After the transfer, the
blots were incubated overnight at 4 °C with polyclonal
antibody against CCR2 (goat, 1:100, Santa Cruz). For load-
ing control, the blots were probed with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (mouse,
1:20000, Millipore). These blots were further incubated
with horseradish peroxidase-conjugated secondary anti-
body, developed in enhanced chemiluminescence solution,
and exposed on Hyperfilm (Bio-Rad, Hercules, CA, USA)
for 1–5 minutes. Specific bands were evaluated by appar-
ent molecular size. The intensity of the selected bands was
analyzed using Image J software (NIH, Bethesda, MD,
USA).
Rotarod test
Mice were trained to maintain their position on a
rotarod (diameter, 3 cm) at 8 rpm for 60 seconds using
the rotarod apparatus (Ugo Basile, Varese, Italy), and
training was considered complete when mice were able
to remain on the rotarod for 60 seconds. After intracis-
ternal injection of RS504393, each mouse was placed
back on the rotarod and latency to fall was recorded.
The cut-off was set at 60 seconds.
Quantification and statistics
The percentage of FG-labeled cells and ATF3-
immunoreactive cells in the TG was quantified in 5 TG
sections of each mouse (3 mice for each group). For
the analysis of CCL2- or GFAP-immunoreactivity, the
images of the brain stem sections from the level of
300 μm rostral to the obex to 1800 μm caudal to the
obex were captured, the dorsomedial quarter of each
section was outlined and a numerical value of the inten-
sity was calculated with a computer-assisted imaging
analysis system (Image J, NIH). The intensity of the
background was subtracted in each section. The data
from 5–6 animals in each group was averaged and ana-
lyzed. For western blot, the density of specific bands was
measured with Image J. All data were expressed as
mean ± SEM. For immunostaining and western blot
studies, differences between two groups (Naïve vs.
IAMNT) were compared using Student t-test. For
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behavioral studies, the data were analyzed with two-way
ANOVA with repeated measurement followed by a
Bonferroni’s post hoc tests. The criterion for statistical
significance was P< 0.05.
Results
Time course of IAMNT-induced heat hyperalgesia
After two days habituation, the basal HWL of the whis-
ker pad to heat stimulus was tested for naïve, IAMNT
and sham-operated mice and they showed similar laten-
cies (Naïve, 12.4 ± 0.7 seconds; IAMNT, 12.9 ± 0.8 sec-
onds; Sham, 12.1 ± 0.7 seconds). The sham-operated and
naïve groups did not show any significant changes at all
time points, and no significant difference was observed
between the sham and the naïve groups (P> 0.05). How-
ever, IAMNT induced significant decrease of HWL of
the ipsilateral whisker pad compared with the sham
group (P< 0.001). HWL decrease appeared on day 3
(7.4 ± 0.5 seconds) and maintained for more than 21 days
(9.6 ± 0.3 seconds) after surgery (Figure 1B). These
results indicate that IAMNT induces persistent trigem-
inal neuropathic pain.
Decrease of FG-labeled neurons and increase of ATF3-IR
neurons in the TG after IAMNT
Two days after FG subcutaneous injection into the
mental skin in naïve mice, many FG-labeled neurons
(53 ± 0.8%) were observed in the mandibular division of
TG (Figure 2A–C). However, few of the FG-labeled neu-
rons were seen in the ophthalmic and maxillary divi-
sions. In IAMNT-operated mice, FG-labeled neurons
were dramatically decreased (4.9 ± 0.7%, P< 0.001) in the
mandibular division (Figure 2B,F). By contrast, the ex-
pression of ATF3, which is a marker of nerve injury [42],
was significantly increased in the ipsilateral TG at 3 days
after IAMNT (Figure 2B,D,G). Compared to naïve ani-
mals, IAMNT operation increased the percentage of
ATF3-IR neurons from 8.1 ± 2.2% to 54.3 ± 5.5%. There
were no significant changes of ATF3 expression in sham-
operated mice (17.1 ± 3.1%, P> 0.05 vs naïve, Figure 2B).
ATF3-IR neurons were also restricted in the mandibular
division of TG and no colocalized FG/ATF3 neurons
were observed (Figure 2E,H).
Upregulation of CCL2 in medullary astrocytes by IAMNT
We checked CCL2 expression from 1 day to 21 days
after IAMNT. As illustrated in Figure 3, IAMNT
increased CCL2 expression at day 3, day 10, and day 21
at the level of 300 μm caudal to the obex (Figure 3A).
No significant increase of CCL2 expression was found in
sham-operated animals (Figure 3Ac). CCL2 immunor-
eactive cells were mainly found in the superficial layers
(Laminae I–III) and medial part of the dorsal horn. The
representative rostro-caudal (from +300 μm to −1800 μm)
Figure 2 The distribution of FG labeled neurons and expression of ATF3 in the TG in naïve, sham-operated, and IAMNT mice. FG-labeled
neurons were mainly distributed in the mandibular division (3rd) of TG in naïve mice (A-C) and decreased after IAMNT (B,F). The ATF3 expression
was increased after IAMNT (B,D,G). No obvious colocalization of FG and ATF3 were found (E,H). *** P< 0.001 (vs naïve). Scale bars, 500 μm in A,
100 μm in C–H. n = 3 for each group.
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Figure 3 The expression of CCL2 in the MDH following IAMNT. (A) Temporal changes of CCL2-IR in the MDH following IAMNT at the level of
300 μm caudal to the obex. The area where the pictures were taken was shown in (a). CCL2-IR was very mild in naïve mice (b), but increased at
3 days (e), 10 days (f), and 21 days (g). CCL2-IR was also mild in the sham-operated mice (c). Scale bar, 50 μm. (B) Spatial changes of CCL2-IR in
the MDH at 10 days after IAMNT. CCL2 expression was increased from 300 μm rostral to the obex (a) to 1500 μm caudal to the obex (g) in the
ipsilateral side. However, no obvious change of CCL2 expression was found in the contralateral side of the MDH. Scale bar, 100 μm.
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photograph of CCL2 expression at 10 days after IAMNT
was shown in Figure 3B. The statistical results of CCL2 ex-
pression from day 1 to day 21 at different levels were
shown in Figure 4. Following IAMNT, CCL2 expression
increased from day 3, peaked at day 10, and maintained at
day 21. The increase of CCL2 expression was mainly in
the ipsilateral MDH. However, at the level of −600 μm,
CCL2 was also increased in the contralateral side at day 3
and day 21 (Figure 4).
To define the cellular distribution of CCL2, we per-
formed double staining of CCL2 with different cell markers.
As shown in Figure 5, CCL2-IR was primarily colocalized
with the astrocytic marker GFAP (Figure 5A–C), but not
with neuronal marker NeuN (Figure 5D–F) or microglial
marker OX-42 (Figure 5G–I), suggesting CCL2 is primarily
induced in astrocytes in the MDH.
Astrocytes activation in the MDH after IAMNT
Because CCL2 is primarily expressed in astrocytes, we
then examined astrocytes activation by checking GFAP
expression in the MDH. In naïve and sham-operated ani-
mals, GFAP-positive astrocytes appeared to be in a
resting state (Figure 6Ab,c). At 1 day after IAMNT, the
astrocyte profiles appeared larger and had more pro-
cesses compared to naïve (Figure 6Ad). Intense astrocytic
responses were discernible in IAMNT animals on day 3
and day 10 (Figure 6Ae,f). We examined spatial changes of
GFAP expression on day 10. As shown in Figure 6B, astro-
cytic activation was found from +300 to −1800 μm. The
activated astrocytes were observed in the medial part of the
superficial dorsal horn where intense CCL2-IR cells
located.
CCR2 upregulation in the MDH neurons after IAMNT
CCR2 is a major type of receptor for CCL2 [43,44]. Western
blot results showed that CCR2 expression in the ipsilateral
medulla was significantly increased at 3, 10 and 21 days after
IAMNT. Sham operated animals did not show obvious in-
crease of CCR2 expression at 3 days (Figure 7A, B).
We then checked the cellular distribution of CCR2 by
double staining of CCR2 with different cell markers. As
shown in Figure 7C, CCR2-IR was primarily colocalized
with the NeuN (Figure 7Ca–c). A few CCR2 positive
cells in the superficial MDH were colocalized with GFAP
(Figure 7Cd–f ) and no cells were colocalized with micro-
glial marker, Iba-1 (Figure 7Cg–i).
Attenuation of IAMNT-induced pain hypersensitivity by
CCR2 antagonist
As the significant upregulation of CCL2 and CCR2 was
observed from day 3 after IAMNT, we speculate CCL2-
CCR2 signaling may be involved the maintenance rather
Figure 4 Rostro-caudal (from+300 μm to −1800 μm) distribution of CCL2-IR in both ipsilateral and contralateral MDH in naïve and
IAMNT-operated animals (1 day, 3 days, 10 days, and 21 days). * P< 0.05, ** P< 0.01, ***P< 0.001 compared to naïve. N, naïve. n = 6 for
naïve, n = 5 for other groups.
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than the development of the trigeminal neuropathic pain.
In addition, reversal of the established pain is more rele-
vant than prevention in clinic. Therefore, we used an ex-
tremely selective CCR2 chemokine receptor antagonist,
RS504393 and tested its analgesic effect by intracisternal
injection at 3 days or 10 days after IAMNT. As shown in
Figure 8A, the IAMNT significantly decreased HWL in
the ipsilateral side at 3 days after the injury. The vehicle
did not affect the IAMNT-induced heat hyperalgesia,
whereas intracisternal injection of 1 μg of RS504393 sig-
nificantly increased the HWL at 1 hour (P< 0.05).
RS504393 at the dose of 10 μg showed stronger effect
than that of 1 μg and the effect started from 30 minutes,
maintained at 3 hours and recovered at 6 hours
(Figure 8A). Similarly, intracisternal injection of 1 μg or
10 μg of RS504393 also blocked the heat hyperalgesia at
10 days after IAMNT (Figure 8B). The effect of
RS504393 was also maintained for more than 3 hours.
To test the effect of RS504393 on basal nociception,
we intracisternally injected 10 μg RS504393 in naïve ani-
mals and tested the HWL. As shown in Figure 8C,
RS405393 at the dose of 10 μg did not affect the HWL
from 30 minutes to 6 hours. The results indicate that
CCR2 may not be involved in the trigeminal nociceptive
pathway in normal conditions.
To evaluate whether antinociceptive doses of CCR2
antagonist are associated with motor dysfunction, a
rotarod test was performed following intracisternal injec-
tion of RS504393 (1, 10 μg). Neither 1 μg nor 10 μg
affected the motor performance at 30 minutes, 1 hour,
and 3 hours after RS504393 administration (data not
shown).
Discussion
In this study, we characterized the morphological and
functional profile of CCL2 and CCR2 in the MDH in
response to peripheral nerve injury. Our results demon-
strated first that IAMNT induced persistent heat hyper-
algesia that was associated with ATF3 expression in the
TG and persistent CCL2 upregulation in the MDH
astrocytes. Second, CCR2, the major receptor of CCL2
was increased from 3 days to 21 days after IAMNT and
CCR2 was mainly expressed in neurons. Third, intracis-
ternal injection of CCR2 antagonist attenuated IAMNT-
induced heat hyperalgesia at 3 days and 10 days after
IAMNT. These data suggest that CCL2-CCR2 signaling
in the MDH play an important role in the maintenance
of orofacial neuropathic pain.
ATF3 is a member of the activating transcription
factor/cAMP-responsive element binding protein (ATF/
Figure 5 Double staining of CCL2 with different cellular markers. CCL2 is mainly colocalized with astrocytic marker GFAP (A–C), but not
with neuronal marker, NeuN (D–F), or microglial marker, OX-42 (G–I). Scale bar, 25 μm.
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Figure 6 The expression of GFAP in the MDH following IAMNT. (A) Temporal changes of GFAP-IR in the MDH following IAMNT at the level of
300 μm caudal to obex. The area where the pictures were taken was shown in (a). GFAP-IR was very mild in naïve mice (b), but increased at
1 day (d), 3 days (e), 10 days (f), and 21 days (g). GFAP-IR was also mild in the sham-operated mice (c). Scale bar, 50 μm. (B) Spatial changes of
GFAP-IR in the MDH at 10 days after IAMNT. GFAP expression was increased from 300 μm rostral to the obex to 1800 μm caudal to the obex in
the ipsilateral side. However, no obvious change of GFAP expression was found in the contralateral side of the MDH. Scale bar, 200 μm.
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CREB) family and has been widely used as a neuronal
marker of nerve injury in the nervous system [42]. In this
study, we observed that ATF3 expression was robustly
increased in the ipsilateral side of mandibular division of
TG, whereas the FG-labeled neurons were significantly
decreased at 3 days after IAMNT. Although ATF3 was
not expressed in the maxillary division of TG, the non-
ATF3-expressing neurons may contribute to the heat
hyperalgesia in the whisker pad area after IAMNT tran-
section. Tsuboi et al. reported that after transection of
the IAN, the A-fiber activities of the ION were signifi-
cantly enhanced and the excitability of TG neurons
innervated by the ION was increased [40]. In addition,
Tsuzuki et al. showed that preprotachykinin mRNA was
increased in the uninjured mandibular neurons after
ION transection [45], suggesting that the intact neurons
may contribute to the secondary hyperalgesia at the gan-
glion level. However, whether CCL2-CCR2 signaling in
the TG is involved in the secondary hyperalgesia needs
to be investigated in the future.
Figure 7 The expression and cellular distribution of CCR2 in the MDH. (A) A representative western blot shows CCR2 expression was
increased in the ipsilateral medulla after IAMNT. (B) Density of CCR2 band, which is normalized to GAPDH loading control and expressed as ratio
of naïve group. * P< 0.05, ** P< 0.01, compared to naïve. ++ P <0.01 compared to sham-operated group. n = 3 for each group. (C) Double
staining of CCR2 with different cellular markers. CCR2 is colocalized with neuronal marker, NeuN (a–c), astrocytic marker GFAP (d–f), but not with
microglial marker Iba-1 (g–i). Scale bar, 25 μm.
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Previous studies have reported that CCL2 is constitu-
tively expressed in small and medium neurons of the
DRG and the expression is upregulated after nerve injury
[28,46]. In the spinal cord, CCL2 expression is also upre-
gulated under neuropathic conditions [29,46,47]. The
present results showed that CCL2 expression was signifi-
cantly increased in the MDH during day 3 to day 21
from the level of obex to −1800 μm caudal to the obex.
The lamina distribution showed that CCL2 was mainly
expressed in laminae I–III of the medial part of the dor-
sal horn. Double staining further showed CCL2 was pre-
dominantly induced in astrocytes after IAMNT, which is
consistent with the following reports. First, the CCL2
upregulation is found in spinal astrocytes after spinal
nerve ligation [47] and spinal cord contusion injuries
[48]. Second, CCL2 is expressed in brain astrocytes
in pathological conditions, such as experimental auto-
immune encephalomyelitis [49-51], brain ischemia
[52,53], traumatic brain damage [54], and Alzheimer’s
disease [55]. Third, in vitro studies show that pri-
mary cultured astrocytes produce CCL2 [47,56-58].
Finally, mice overexpressing CCL2 in astrocytes dis-
play enhanced nociceptive responses [26]. However,
we do not exclude the possibility that IAMNT could
induce CCL2 release from the central terminals of
primary afferents, as previous studies showed that
CCL2 is expressed in CGRP-immunoreactive primary
afferents in the spinal cord and increased under
neuropathic conditions [29,46].
It is becoming clear that astrocytes and microglia are
activated after peripheral nerve injury or inflammation
[59-61], and glial activation might be a causal factor in
the pain hypersensitivity at the spinal level. Similarly,
glial activation was also induced in the MDH after tri-
geminal nerve ligation or transection [9-11,36], orofacial
inflammation [11,62], and tumor cells inoculation in the
vibrissal pad [63]. Consistent with these studies, we
found that the astrocytes in the MDH changed their
morphological features and manifested large somata with
many thick processes from 3 days to 21 days after
IAMNT. In addition, the astrocytic activation was corre-
lated with the heat hyperalgesia behavior and CCL2
upregulation. Okada-Ogawa et al. have reported that
medullary application of the astroglial metabolic inhibi-
tor sodium fluoroacetate attenuated heat hyperalgesia at
7 days after the IAN transection in rats [36], supporting
the view that medullary astrocytes are involved in the
maintenance of orofacial neuropathic pain.
Astrocytes are the most abundant cells and have
a close contact with neurons and blood vessels. They not
only support and nourish neurons but also regulate
nearby neuronal excitability and glial functions by the
release of gliotransmitters such as ATP, glutamate,
growth factors (BDNF, bFGF), proinflammatory cytokines
Figure 8 The effect of RS504393 on IAMNT-induced heat
hyperalgesia. Intracisternal injection of RS504393, given at 3 days (A)
or 10 days (B) after IAMNT, significantly reduced heat hyperalgesia on
the ipsilateral facial skin. However, 10 μg RS50439310 did not affect the
HWL in naive animals (C). * P< 0.05, ** P< 0.01, 1 μg RS504393 versus
vehicle; + P< 0.05, ++ P< 0.01, +++ P< 0.001, 10 μg RS504393 versus
vehicle. BL, baseline.
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(e.g. IL-1β, TNF-α), and chemokines (CCL2, CXCL1,
CXCL10) [47,62,64,65]. Glial–neuronal interaction has
been implicated to contribute to central sensitization
under pathological conditions [32]. For example, IL-1β is a
major proinflammatory cytokine and upregulated in astro-
cytes in chronic pain conditions [62,66,67] . Immunostain-
ing shows that IL-1 receptor type 1 colocalizes with the N-
Methyl-D-aspartate (NMDA) receptor NR1 subunits in
neurons of the spinal cord [68], trigeminal nucleus [62],
and rostral ventromedial medulla [67]. Importantly, IL-1β
can directly modulate synaptic transmission in the spinal
cord by enhancing excitatory synaptic transmission and
suppressing inhibitory synaptic transmission [69]. Here,
CCL2 was clearly shown in medullary astrocytes, and its
preferred receptor, CCR2 was mainly expressed in neu-
rons, indicating that CCL2-CCR2 might be involved in the
astroglial–neuronal signaling in the MDH.
Although our immunostaining results showed the pre-
dominant expression of CCR2 in neurons, the cellular
localization of CCR2 in the central nervous system is
heavily debated. An early immunohistochemical study
shows CCR2 expression in spinal microglia and spinal
administration of CCL2 activates microglia [24,25]. How-
ever, the presence of CCR2 in microglia has recently
been questioned by the work of Saederup, demonstrating
a CCR2 expressing population of cells did not express
CX3CR1, which is known to be expressed exclusively in
microglia [70]. This suggests microglia might not express
CCR2, and CCR2 positive cells are perhaps infiltrating
monocytes [33,70]. The expression of CCR2 in neurons
can be supported by recent evidence. It has been
reported that CCR2–green fluorescent protein (GFP) re-
porter mice [27] show a weak but clear GFP signal in
dorsal horn neurons [47]. In situ hybridization studies
showed that CCR2 mRNA was increased in dorsal horn
neurons after spinal nerve ligation [47]. Spinal adminis-
tration of CCL2 induces extracellular signal-regulated
kinase activation in the spinal cord neurons [47,71]. Fur-
thermore, CCL2 rapidly increases spontaneous excitatory
postsynaptic currents and NMDA-induced current [47]
and inhibits GABA-induced currents [72] in dorsal horn
neurons. CCR2 has also been shown to be upregulated
in the spinal astrocytes following spinal cord injury [48]
and hippocampal astrocytes after status epilepticus [73].
In agreement with these results, our results showed few
CCR2-IR cells were also observed in astrocytes in the
superficial dorsal horn.
It has been reported that CCR2 is increased in the
DRG or spinal cord following partial sciatic nerve injury
or spinal nerve ligation [24,47]. The present study fur-
ther showed a persistent increase of CCR2 protein in the
ipsilateral medulla after IAMNT. In parallel with these
results, behavioral data showed that inhibition of CCR2
by intracisternal injection of RS504393 attenuated
IAMNT-induced heat hyperalgesia of the whisker pad
area at both 3 days and 10 days after the surgery, indicat-
ing that CCR2 in the MDH contribute to the secondary
hyperalgesia. The previous results showed that the use of
CCR2 receptor antagonists or blocking antibodies suc-
cessfully inhibited nociceptive signaling [71,74-76]. In
addition, mice lacking CCR2 display reduced mechanical
allodynia after partial ligation of the sciatic nerve [24,25].
These data indicate that CCR2 play a key role in the
maintenance of neuropathic pain at both the spinal and
trigeminal level.
Conclusions
In this study, we demonstrated that CCL2 and CCR2
were persistently increased in the MDH following
IAMNT with the CCL2 expression in activated astro-
cytes and CCR2 expression in neurons. Inhibition of
CCR2 by selective CCR2 antagonist attenuated IAMNT-
induced secondary heat hyperalgesia. These data indicate
that CCL2 and CCR2 in the trigeminal spinal subnucleus
caudalis can serve as signaling molecules between astro-
cytes and neurons and contribute to the maintenance of
neuropathic pain. Targeting the CCL2/CCR2 pathway
may provide a novel therapeutic approach for the treat-
ment of the trigeminal neuralgia.
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